Vyalova N M, Pozhidaev I V, Osmanova D Z, Simutkin G G, Ivanova S А, Bokhan N A
Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia.
Mental Health Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russia; National Research Tomsk State University, Tomsk, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(5):58-61. doi: 10.17116/jnevro20171175158-61.
To study the association between polymorphisms of PIP5K2A and HTR2C genes and response to antidepressant therapy in patients with a current depressive episode.
The study included 222 patients (168 women and 54 men) with a current depressive episode. The assessment of the severity of the current depressive episode and the efficacy of treatment was performed using the Hamilton depression scale (HDRS-17) and the Clinical global impression scale (CGI-S, CGI-I). The association of treatment efficacy with PIP5K2A polymorphisms rs10430590, rs10828317 and HTR2C polymorphisms rs6318, rs569959, rs3813929, rs12858300 was studied.
Polymorphisms rs10828317 and rs10430590 in the PIP5K2A gene were associated with the CGI-S total score at day 28 of therapy. Polymorphism rs6318 in the HTR2C gene was associated with response to antidepressant therapy followed by clinical improvement of patients with current depressive episode on the 28th day of antidepressant therapy.
研究磷脂酰肌醇-4-磷酸5-激酶2A（PIP5K2A）基因和5-羟色胺受体2C（HTR2C）基因多态性与当前抑郁发作患者抗抑郁治疗反应之间的关联。
该研究纳入了222例当前有抑郁发作的患者（168名女性和54名男性）。使用汉密尔顿抑郁量表（HDRS-17）和临床总体印象量表（CGI-S、CGI-I）对当前抑郁发作的严重程度和治疗效果进行评估。研究了治疗效果与PIP5K2A基因多态性rs10430590、rs10828317以及HTR2C基因多态性rs6318、rs569959、rs3813929、rs12858300之间的关联。
PIP5K2A基因中的多态性rs10828317和rs10430590与治疗第28天的CGI-S总分相关。HTR2C基因中的多态性rs6318与抗抑郁治疗反应相关，随后在抗抑郁治疗第28天当前抑郁发作患者的临床症状得到改善。
